13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05081271 (ClinicalTrials.gov) | October 2021 | 14/10/2021 | COVID-19 Booster Vaccination in Persons With Multiple Sclerosis | COVID-19 Booster Vaccination in Persons With Multiple Sclerosis | PWMS Who Have Completed Vaccination Against COVID-19 and Test Negative for COVID-19 Spike Protein Antibodies Using a Commercial Assay | Biological: Homologous booster;Biological: Heterologous booster | Griffin Hospital | Yale-Griffin Prevention Research Center | Not yet recruiting | 18 Years | N/A | All | 60 | N/A | NULL |